Neogenomics Inc Stock Price, News & Analysis

NeoGenomics (NASDAQ: NEO) reported third quarter 2025 results for the period ended September 30, 2025. Consolidated revenue rose 12% YoY to $188 million, driven by clinical revenue +18% and NGS revenue +24%, with NGS representing nearly one-third of clinical revenue. Revenue per clinical test increased 3% to $476. Net loss widened 53% to $27 million and Adjusted EBITDA fell 9% to $12.2 million. Cash and marketable securities totaled $164 million. The company re-affirmed full-year 2025 guidance of $720–$726 million revenue and retained its prior adjusted EBITDA and net loss ranges.

NeoGenomics (NASDAQ: NEO) will highlight its RaDaR ST molecular residual disease (MRD) circulating tumor DNA assay at the ESMO Congress 2025, October 17–21 in Berlin.

The company said RaDaR ST uses whole-exome sequencing from tumor samples plus advanced bioinformatics to create patient-specific MRD panels, applying high-depth sequencing and personalized design to sensitively detect ctDNA in plasma and track tumor dynamics and treatment response. NeoGenomics will present three new posters from European collaborators, note interventional therapy trials in progress, and feature RaDaR ST and broader oncology testing at booth #4012.

NeoGenomics (NASDAQ: NEO) will report third quarter 2025 financial results before U.S. market open on Tuesday, October 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to discuss results and recent highlights.

Investors can access the live webcast via the company's Investor Relations site at ir.neogenomics.com. The webcast will be archived and available for replay. To join by phone, dial (888) 506-0062 (U.S.) or (973) 528-0011 (international) and use participant code 392611.

NeoGenomics (NASDAQ:NEO) has secured a significant legal victory as the District Court for the Middle District of North Carolina granted summary judgment in its patent infringement lawsuit against Natera. The Court ruled that Natera's asserted patent claims are invalid for claiming ineligible subject matter.

This ruling allows NeoGenomics to freely commercialize its RaDaR ST molecular residual disease (MRD) assay in the United States. The company has already launched RaDaR ST to biopharma customers and has submitted for clinical reimbursement coverage through CMS's MolDX program.

NeoGenomics (NASDAQ: NEO) has launched NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test designed for advanced solid tumors. The new test analyzes over 500 genes, including MSI and bTMB markers, with a 7-day turnaround time.

PanTracer LBx enables therapy selection, trial matching, and disease monitoring through a simple blood draw when tissue samples are limited or unavailable. This strategic launch positions NeoGenomics in the $3-5 billion liquid biopsy market, complementing their existing tissue-based testing portfolio and expanding their addressable market.

NeoGenomics (NASDAQ: NEO) reported Q2 2025 results with consolidated revenue increasing 10% to $181 million. Clinical revenue grew 16%, with 13% growth excluding the Pathline acquisition. The company's average revenue per clinical test increased 2% to $465, driven by higher-value tests and strategic reimbursement initiatives.

Despite revenue growth, NEO reported a net loss of $45 million, up 142% year-over-year, primarily due to $20 million in impairment charges. Adjusted EBITDA remained relatively flat at $10.7 million. The company completed the acquisition of Pathline for $8 million plus contingent consideration.

NeoGenomics revised its full-year 2025 guidance downward, now expecting revenue of $720-726 million (9-10% growth) and increased net loss projections to $108-116 million, citing pressure in pharma revenue and delays in the PanTracer™ Liquid Biopsy launch.

NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its second quarter 2025 financial results announcement for July 29, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and recent highlights.

Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants can dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 859170.

NeoGenomics (NASDAQ: NEO) has launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, along with PanTracer Tissue + HRD option for enhanced tumor analysis. The new assay evaluates over 500 cancer-related genes and can deliver results in as little as 8 days.

PanTracer Tissue + HRD specifically targets ovarian cancer diagnostics by incorporating homologous recombination deficiency analysis, BRCA mutation status, and genomic instability score in a single test. These biomarkers are crucial for guiding PARP inhibitor treatments and therapies targeting DNA repair pathways.

The new offerings, revealed at the 2025 ASCO Annual Meeting, represent an upgrade to the company's previous NeoComprehensive® Solid Tumor platform, featuring minimal specimen requirements and alignment with clinical guidelines for therapy selection and clinical trial enrollment.

NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has appointed Dr. Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green currently serves as Senior Vice President and Head of Oncology, Global Clinical Development at Merck, overseeing the company's largest commercial revenue and pipeline investment area.

Dr. Green brings extensive experience in clinical oncology and pipeline development, having previously held leadership positions at Seagen and Genentech. She began her career as a Medical Oncologist at MD Anderson Cancer Center, where she later became Medical Director of the Nellie B. Connally Breast Center.